Home Pharmaceutical asia-pacific-active-pharmaceutical-ingredient-api-market

Pharmaceutical

Image

Asia-Pacific Active Pharmaceutical Ingredients (API) Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Published Report
  • Apr 2021
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 419
  • No of Figures: 38

Asia-Pacific Active Pharmaceutical Ingredients (API) Market, By Molecule (Small Molecule, Large Molecule), Type (Innovative Active Pharmaceutical Ingredients, Generic Innovative Active Pharmaceutical Ingredients), Type of Manufacturer (Captive API Manufacturer, Merchant API Manufacturer), Synthesis (Synthetic Active Pharmaceutical Ingredients and Biotech Active Pharmaceutical Ingredients), Chemical Synthesis (Acetaminophen, Artemisinin, Saxagliptin, Sodium Chloride, Ibuprofen, Losartan Potassium, Enoxaparin Sodium, Rufinamide, Naproxen, Tamoxifen, Others), Type of Drug (Prescription Drugs, Over-the-Counter), Usage (Clinical, Research), Potency (Low-to-Moderate Potency Active Pharmaceutical Ingredients, Potent-to-Highly Potent Active Pharmaceutical Ingredient), Therapeutic Application (Cardiology, CNS & Neurology, Oncology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, Other Therapeutic Application), Country (Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2028

Asia-Pacific Active Pharmaceutical Ingredients (API) Market

Market Analysis and Insights: Asia-Pacific Active Pharmaceutical Ingredients (API) Market

The active pharmaceutical ingredients (API) market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.5% in the forecast period of 2021 to 2028 and is expected to reach USD 86,222.48 million by 2028. Increasing prevalence of various chronic disorders and increase in aging population are the major drivers which propelled the demand of the active pharmaceutical ingredients (API) market in the forecast period.

  • In Greek, the traditional word for active pharmaceutical ingredients (API) is called pharmacon or pharmakon which symbolizes a magical substance or drug. Active pharmaceutical ingredients as described in ICH Q7 are “any substance or combination of substances intended to be used in the manufacturing of a drug product which when used in the production of the drug becomes an active pharmaceutical ingredient. Such substances are used to provide pharmacological activity.

Increase in technological advancements will enhance the capabilities and boost the manufacturing skills of the market players that the manufacturers have to provide APIs in bulk and meet the demand of the consumers which can drive the growth of the active pharmaceutical ingredients (API) market. Availability of sub-standard and counterfeit drugs is acting as a restraint for hampering the demand of the active pharmaceutical ingredients (API) market. Rising investment in research regarding the development of APIs will further increase the growth opportunities for the active pharmaceutical ingredients (API) market. Disruption in the supply chain of APIs during COVID-19 acts challenging for the healthcare providers which may challenge the active pharmaceutical ingredients (API) market.

The active pharmaceutical ingredients (API) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

Asia-Pacific Active Pharmaceutical Ingredients (API) Market

Asia-Pacific Active Pharmaceutical Ingredients (API) Market Scope and Market Size

The active pharmaceutical ingredients (API) market is segmented on the basis of the molecule, type, type of manufacturer, synthesis, chemical synthesis, type of drug, usage, potency and therapeutic application. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of molecule, the active pharmaceutical ingredients (API) market is segmented into small molecule and large molecule. In 2021, small molecule segment is expected to dominate the active pharmaceutical ingredients (API) market due to increasing number of regulatory approval and rising research and development on novel small molecules due to their high penetration power.
  • On the basis of type, the active pharmaceutical ingredients (API) market is segmented into innovative active pharmaceutical ingredients and generic active pharmaceutical ingredients. In 2021, innovative active pharmaceutical ingredients segment is expected to dominate the active pharmaceutical ingredients (API) market because of high cost of innovative APIs in comparison to generic APIs and rising FDA approval for the new molecular entities.
  • On the basis of type of manufacturer, the active pharmaceutical ingredients (API) market is segmented into captive API manufacturer and merchant API manufacturer. In 2021, captive API manufacturer segment is expected to dominate the active pharmaceutical ingredients (API) market due to huge investment by major market players to generate high end manufacturing facilities and easy availability of raw materials.
  • On the basis of synthesis, the active pharmaceutical ingredients (API) market is segmented into synthetic active pharmaceutical ingredients and biotech active pharmaceutical ingredients. In 2021, synthetic active pharmaceutical ingredients segment is expected to dominate the active pharmaceutical ingredients (API) market because of easy protocol for the synthesis of molecules, less stringent regulatory guidelines and in the coming years, many synthetic molecules goes off patent.
  • On the basis of chemical synthesis, the active pharmaceutical ingredients (API) market is segmented into acetaminophen, artemisinin, saxagliptin, sodium chloride, ibuprofen losartan potassium, enoxaparin sodium, rufinamide, naproxen, tamoxifen and others. In 2021, saxagliptin segment is expected to dominate the active pharmaceutical ingredients (API) market due to high cost of the API and rising diabetes cases worldwide.
  • On the basis of type of drug, the active pharmaceutical ingredients (API) market is segmented into prescription drugs and over-the-counter drugs. In 2021, prescription drugs segment is dominating the active pharmaceutical ingredients (API) market because of high cost of the drugs which will increase the APIs and manufacturing cost of the APIs.
  • On the basis of usage, the active pharmaceutical ingredients (API) market is segmented into clinical and research. In 2021, clinical segment is expected to dominate the active pharmaceutical ingredients (API) market because of rising number of diseases which required continuous supply of APIs and raw material.
  • On the basis of potency, the active pharmaceutical ingredients (API) market is segmented into low-to-moderate potency active pharmaceutical ingredients and potent-to-highly potent active pharmaceutical ingredient. In 2021, low-to-moderate potency active pharmaceutical ingredients segment is expected to dominate the active pharmaceutical ingredients (API) market because of their less toxicity and less hazard nature.
  • On the basis of therapeutic application, the active pharmaceutical ingredients (API) market is segmented into cardiology, CNS & neurology, oncology, orthopedic, endocrinology, pulmonology, gastroenterology, nephrology, ophthalmology and other therapeutic application. In 2021, cardiology segment is expected to dominate the active pharmaceutical ingredients (API) market because of rising number of cardiac diseases such as heart attack, embolism and others.

Active Pharmaceutical Ingredients (API) Market Country Level Analysis

The active pharmaceutical ingredients (API) market is analyzed and market size information is provided on the basis of the country, molecule, type, type of manufacturer, synthesis, chemical synthesis, type of drug, usage, potency and therapeutic application as referenced above.

The countries covered in the Asia-Pacific active pharmaceutical ingredients (API) market report are the Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific.

China is dominating in the Asia-Pacific active pharmaceutical ingredients (API) market owing to government initiatives for the production of APIs.   

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Increasing Prevalence of Various Chronic Disorders is boosting the Growth of Active Pharmaceutical Ingredients (API) Market

The active pharmaceutical ingredients (API) market also provides you with detailed market analysis for every country growth in active pharmaceutical ingredients (API) industry with active pharmaceutical ingredients (API) drugs sales, impact of advancement in the active pharmaceutical ingredients (API) technology and changes in regulatory scenarios with their support for the active pharmaceutical ingredients (API) market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Active Pharmaceutical Ingredients (API) Market Share Analysis

The active pharmaceutical ingredients (API) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to active pharmaceutical ingredients (API) market.

The major companies which are dealing in the active pharmaceutical ingredients (API) are Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi, GlaxoSmithKline plc., Aarti Industries Limited, Recipharm AB,Jubilant Pharmova Limited, LUPIN, Aurobindo Pharma, , AbbVie Inc., AstraZeneca, Alkem Labs, Albemarle Corporation, Saneca Pharmaceuticals, Unichem Laboratories, Neuland Laboratories Ltd., Divi's Laboratories Limited., HIKAL Ltd., Viatris Inc. , Merck KGaA, Novo Nordisk A/S, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.,  BASF SE, Piramal Pharma Solutions, among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately. 

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the active pharmaceutical ingredients (API) market.

For instance,

  • In December 2019, AbbVie Inc. collaborated with Scripps Research in order to boost up the research for new drug discovery targeting a range of diseases, including areas on oncology, immunology among others. As per the collaboration agreement Scripps Research will conduct the pre-clinical research activities for development of novel therapies. This collaboration helped the company to advance up its novel medicines for patients that has ultimately boosted company’s revenue.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market players is enhancing the company market in the active pharmaceutical ingredients (API) market which also provides the benefit for organization to improve their offering for active pharmaceutical ingredients (API).

SKU-

TABLE 1 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, PIPELINE ANALYSIS

TABLE 2 DIFFERENCE BETWEEN THE U.S. AND EU FOR THE REGISTRATION PROCESS

TABLE 3 DIFFERENCE BETWEEN THE U.S. AND EU FOR THE ADMINISTRATIVE REQUIREMENTS

TABLE 4 AGE DISTRIBUTION OF THE U.K. POPULATION (FROM 1976 TO 2046)

TABLE 5 WORLD –WIDE IMPACT OF COVID-19 ON THE PHARMACEUTICAL SECTOR

TABLE 6 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 7 ASIA-PACIFIC SMALL MOLECULE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 8 ASIA-PACIFIC LARGE MOLECULE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 9 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 10 ASIA-PACIFIC INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 11 ASIA-PACIFIC GENERIC ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 12 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURERS, 2017-2028 (USD MILLION)

TABLE 13 ASIA-PACIFIC CAPTIVE API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 14 ASIA-PACIFIC MERCHANT API MANUFACTURER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET , BY REGION, 2017-2028 (USD MILLION)

TABLE 15 ASIA-PACIFIC TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 16 ASIA-PACIFIC TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 17 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 18 ASIA-PACIFIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 19 ASIA-PACIFIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 20 ASIA-PACIFIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 21 ASIA-PACIFIC TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 22 ASIA-PACIFIC PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 23 ASIA-PACIFIC MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 24 ASIA-PACIFIC CYTOKINESPRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 25 ASIA-PACIFIC EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 26 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (USD MILLION)

TABLE 27 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (UNITS)

TABLE 28 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (ASP)

TABLE 29 ASIA-PACIFIC SAXAGLIPTIN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, REGION, 2017-2028 (USD MILLION)

TABLE 30 ASIA-PACIFIC ENOXAPARIN SODIUM IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 31 ASIA-PACIFIC RUFINAMIDE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 32 ASIA-PACIFIC TAMOXIFEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 33 ASIA-PACIFIC ARTEMISININ IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 34 ASIA-PACIFIC LOSARTAN POTASSIUM IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 35 ASIA-PACIFIC NAPROXEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 36 ASIA-PACIFIC IBUPROFEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 37 ASIA-PACIFIC ACETAMINOPHEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 38 ASIA-PACIFIC SODIUM CHLORIDE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 39 ASIA-PACIFIC OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 40 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2019-2028 (USD MILLION)

TABLE 41 ASIA-PACIFIC PRESCRIPTION DRUGS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 42 ASIA-PACIFIC OVER-THE-COUNTER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 43 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 44 ASIA-PACIFIC CLINICAL IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 45 ASIA-PACIFIC OVER-THE-COUNTER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 46 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 47 ASIA-PACIFIC LOW-TO-MODERATE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 48 ASIA-PACIFIC POTENT-TO-HIGHLY POTENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 49 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 50 ASIA-PACIFIC CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 51 ASIA-PACIFIC CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 52 ASIA-PACIFIC CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 53 ASIA-PACIFIC CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 54 ASIA-PACIFIC ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 55 ASIA-PACIFIC ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 56 ASIA-PACIFIC GASTROENTEROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 57 ASIA-PACIFIC GASTROENTEROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 58 ASIA-PACIFIC PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 59 ASIA-PACIFIC PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 60 ASIA-PACIFIC ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 61 ASIA-PACIFIC ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 62 ASIA-PACIFIC NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 63 ASIA-PACIFIC NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 64 ASIA-PACIFIC ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 65 ASIA-PACIFIC ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 66 ASIA-PACIFIC OPHTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 67 ASIA-PACIFIC OPHTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 68 ASIA-PACIFIC OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 69 ASIA-PACIFIC OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 70 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY COUNTRY, 2018-2028 (USD MILLION)

TABLE 71 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 72 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 73 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 74 ASIA-PACIFIC TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 75 ASIA-PACIFIC TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 76 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 77 ASIA-PACIFIC SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 78 ASIA-PACIFIC TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 79 ASIA-PACIFIC PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 80 ASIA-PACIFIC MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 81 ASIA-PACIFIC CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 82 ASIA-PACIFIC EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 83 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 84 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 85 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 86 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 87 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 88 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 89 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 90 ASIA-PACIFIC CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 91 ASIA-PACIFIC CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 92 ASIA-PACIFIC ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 93 ASIA-PACIFIC GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 94 ASIA-PACIFIC PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 95 ASIA-PACIFIC ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 96 ASIA-PACIFIC NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 97 ASIA-PACIFIC ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 98 ASIA-PACIFIC OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 99 ASIA-PACIFIC OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 100 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 101 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 102 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 103 CHINA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 104 CHINA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 105 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 106 CHINA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 107 CHINA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 108 CHINA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 109 CHINA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 110 CHINA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 111 CHINA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 112 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 113 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 114 UDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 115 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 116 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 117 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 118 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 119 CHINA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 120 CHINA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 121 CHINA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 122 CHINA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 123 CHINA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 124 CHINA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 125 CHINA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 126 CHINA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 127 CHINA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 128 CHINA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 129 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 130 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 131 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 132 INDIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 133 INDIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 134 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 135 INDIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 136 INDIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 137 INDIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 138 INDIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 139 INDIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 140 INDIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 141 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 142 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 143 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 144 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 145 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 146 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 147 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 148 INDIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 149 INDIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 150 INDIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 151 INDIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 152 INDIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 153 INDIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 154 INDIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 155 INDIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 156 INDIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 157 INDIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 158 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 159 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 160 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 161 JAPAN TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 162 JAPAN TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 163 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 164 JAPAN SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 165 JAPAN TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 166 JAPAN PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 167 JAPAN MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 168 JAPAN CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 169 JAPAN EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 170 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 171 AE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 172 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 173 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 174 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 175 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 176 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 177 JAPAN CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 178 JAPAN CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 179 JAPAN ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 180 JAPAN GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 181 JAPAN PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 182 JAPAN ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 183 JAPAN NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 184 JAPAN ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 185 JAPAN OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 186 JAPAN OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 187 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 188 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 189 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 190 AUSTRALIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 191 AUSTRALIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 192 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 193 AUSTRALIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 194 AUSTRALIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 195 AUSTRALIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 196 AUSTRALIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 197 AUSTRALIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 198 AUSTRALIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 199 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 200 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 201 ISREAL ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 202 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 203 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 204 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 205 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 206 AUSTRALIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 207 AUSTRALIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 208 AUSTRALIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 209 AUSTRALIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 210 AUSTRALIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 211 AUSTRALIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 212 AUSTRALIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 213 AUSTRALIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 214 AUSTRALIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 215 AUSTRALIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 216 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 217 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 218 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 219 SOUTH KOREA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 220 SOUTH KOREA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 221 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 222 SOUTH KOREA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 223 SOUTH KOREA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 224 SOUTH KOREA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 225 SOUTH KOREA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 226 SOUTH KOREA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 227 SOUTH KOREA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 228 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 229 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 230 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 231 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 232 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 233 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 234 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 235 SOUTH KOREA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 236 SOUTH KOREA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 237 SOUTH KOREA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 238 SOUTH KOREA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 239 SOUTH KOREA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 240 SOUTH KOREA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 241 SOUTH KOREA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 242 SOUTH KOREA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 243 SOUTH KOREA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 244 SOUTH KOREA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 245 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 246 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 247 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 248 SINGAPORE TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 249 SINGAPORE TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 250 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 251 SINGAPORE SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 252 SINGAPORE TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 253 SINGAPORE PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 254 SINGAPORE MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 255 SINGAPORE CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 256 SINGAPORE EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 257 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 258 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 259 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 260 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 261 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 262 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 263 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 264 SINGAPORE CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 265 SINGAPORE CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 266 SINGAPORE ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 267 SINGAPORE GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 268 SINGAPORE PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 269 SINGAPORE ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 270 SINGAPORE NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 271 SINGAPORE ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 272 SINGAPORE OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 273 SINGAPORE OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 274 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 275 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 276 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 277 MALAYSIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 278 MALAYSIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 279 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 280 MALAYSIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 281 MALAYSIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 282 MALAYSIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 283 MALAYSIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 284 MALAYSIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 285 MALAYSIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 286 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 287 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 288 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 289 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 290 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 291 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 292 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 293 MALAYSIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 294 MALAYSIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 295 MALAYSIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 296 MALAYSIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 297 MALAYSIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 298 MALAYSIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 299 MALAYSIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 300 MALAYSIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 301 MALAYSIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 302 MALAYSIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 303 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 304 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 305 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 306 THAILAND TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 307 THAILAND TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 308 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 309 THAILAND SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 310 THAILAND TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 311 THAILAND PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 312 THAILAND MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 313 THAILAND CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 314 THAILAND EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 315 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 316 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 317 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 318 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 319 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 320 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 321 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 322 THAILAND CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 323 THAILAND CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 324 THAILAND ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 325 THAILAND GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 326 THAILAND PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 327 THAILAND ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 328 THAILAND NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 329 THAILAND ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 330 THAILAND OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 331 THAILAND OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 332 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 333 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 334 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 335 INDONESIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 336 INDONESIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 337 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 338 INDONESIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 339 INDONESIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 340 INDONESIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 341 INDONESIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 342 INDONESIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 343 INDONESIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 344 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 345 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 346 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 347 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 348 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 349 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 350 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 351 INDONESIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 352 INDONESIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 353 INDONESIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 354 INDONESIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 355 INDONESIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 356 INDONESIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 357 INDONESIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 358 INDONESIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 359 INDONESIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 360 INDONESIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 361 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 362 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 363 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 364 PHILIPPINES TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 365 PHILIPPINES TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 366 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 367 PHILIPPINES SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 368 PHILIPPINES TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 369 PHILIPPINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 370 PHILIPPINES MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 371 PHILIPPINES CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 372 PHILIPPINES EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 373 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 374 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 375 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 376 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 377 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 378 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 379 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 380 PHILIPPINES CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 381 PHILIPPINES CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 382 PHILIPPINES ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 383 PHILIPPINES GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 384 PHILIPPINES PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 385 PHILIPPINES ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 386 PHILIPPINES NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 387 PHILIPPINES ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 388 PHILIPPINES OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 389 PHILIPPINES OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 390 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 391 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 392 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 393 VIETNAM TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 394 VIETNAM TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 395 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 396 VIETNAM SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 397 VIETNAM TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 398 VIETNAM PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 399 VIETNAM MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 400 VIETNAM CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 401 VIETNAM EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 402 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 403 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 404 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 405 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 406 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 407 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 408 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 409 VIETNAM CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 410 VIETNAM CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 411 VIETNAM ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 412 VIETNAM GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 413 VIETNAM PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 414 VIETNAM ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 415 VIETNAM NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 416 VIETNAM ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 417 VIETNAM OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 418 VIETNAM OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 419 REST OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Asia-Pacific active pharmaceutical ingredients (API) market is expected to grow at a CAGR of 7.5% during the forecast period of 2021 to 2028.
The future market of the Asia-Pacific active pharmaceutical ingredients (API) market is expected to reach USD 86,222.48 million by 2028.
The major players in the Asia-Pacific active pharmaceutical ingredients (API) market are Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi, GlaxoSmithKline plc., Aarti Industries Limited, Recipharm AB, Jubilant Pharmova Limited, LUPIN, Aurobindo Pharma, AbbVie Inc., AstraZeneca, Alkem Labs, Albemarle Corporation, Saneca Pharmaceuticals, Unichem Laboratories, Neuland Laboratories Ltd., Divi's Laboratories Limited., HIKAL Ltd., etc.
The countries covered in the Asia-Pacific active pharmaceutical ingredients (API) market are Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific.

BROWSE RELATED REPORTS

Global Active Pharmaceutical Ingredient (API) Market – Industry Trends and Forecast to 2031
North America Active Pharmaceutical Ingredients (API) Market – Industry Trends and Forecast to 2031
Europe Active Pharmaceutical Ingredients (API) Market – Industry Trends and Forecast to 2030
Middle East and Africa Active Pharmaceutical Ingredients (API) Market – Industry Trends and Forecast to 2030
Vietnam Active Pharmaceutical Ingredients (API) Market – Industry Trends and Forecast to 2030

BROWSE RELATED Blogs

Active Pharmaceutical Ingredient (API): A Critical Review of Current Biotechnological Approaches

BROWSE RELATED Press Release

Rising Incidence of Chronic Diseases Drives the Market Growth
Increasing Prevalence of Various Chronic Disease Drives the Growth of the Vietnam Active Pharmaceutical Ingredients (API) Market
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Can be used by entire organization across the globe + Downloadable and Printable PDF + 30 + Countries

Buy Now
Request for TOC Speak to Analyst Inquire Before Buying Free Sample Report
Advance Formative Research Customization Request for bulk Reports

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials

David Manning - Thermo Fisher Scientific
Director, Global Strategic Accounts,

Dear Ricky,
I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.

Image
Manager - Market Analytics,
Uriah D. Avila - Zeus Polymer Solutions

Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.

Business Development Manager,
(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC

DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.

Image
Business Intelligence and Analytics,
Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst,
Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director,
Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO,
A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director,
Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager,
Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations,
GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst,
Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager,
Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment
MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer
Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro
Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department)
UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future